Clinical Insights & Updates

5
NOV

Immuron's ASH Phase II Trial Update

 

Immuron's Alcoholic Steatohepatitis (ASH)  Update:

Immuron has joined forces with the US National Institute of Health to conduct a clinical trial in Alcoholic Steatohepatitis (ASH).

IMM-124E was chosen as only one of three candidates evaluated by the NIH for this fully funded trial.

The Study Headed by Virginia Commonwealth University (VCU) is a multi-centre randomized controlled study which is intended to demonstrate the efficacy of IMM-124E as a treatment for ASH compared to placebo. The study is expected to enroll 66 patients of which approximately 24 have already been randomized and dosed.

11
SEP

Immuron's NASH Phase II

Scientific Team

Immuron is currently running a multi-national, randomized controlled clinical study in the USA, Australia, and Israel.  More than 20 sites across the world are participating including, Duke University, Cleveland Clinic, Universities of Virginia, Virginia Commonwealth, and prestigious Hospitals in these countries.

Many of the worlds leaders in NASH and Hepatology are involved in this study including Professor Arun Sanyal.

The Study is designed to evaluate the effect of IMM-124E on patients with NASH compared to placebo after 6 months of treatment.  A total of 120 patients are expected to enroll in the study and the company is close to reaching 30% of this milestone.